JPMorgan Downgrades Zimmer Biomet (ZBH) to Neutral

JPMorgan analyst Robbie Marcus downgraded Zimmer Biomet (NYSE: ZBH) from Overweight to Neutral with a price target of $118.00 (from $140.00).

The analyst still likes the LT outlook for the company but steps to sidelines citing a belief that 2019 will experience limited upside to Street expectations as the year appears to be another transition year.

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $105.78 yesterday.

You May Also Be Interested In

• Zura Bio Ltd. (ZURA) PT Raised to $20 at Guggenheim
• BTIG Downgrades Apogee Therapeutics Inc (APGE) to Neutral
• Expedia (EXPE) PT Raised to $351 at UBS